Insider Transactions in Q1 2023 at Crinetics Pharmaceuticals, Inc. (CRNX)
Insider Transaction List (Q1 2023)
| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|---|---|---|---|---|---|
|
Mar 16
2023
|
Richard Scott Struthers President & CEO |
SELL
Payment of exercise price or tax liability
|
Direct |
4,628
-3.56%
|
$78,676
$17.12 P/Share
|
|
Mar 16
2023
|
Marc Wilson CFO |
SELL
Payment of exercise price or tax liability
|
Direct |
1,666
-1.55%
|
$28,322
$17.12 P/Share
|
|
Mar 16
2023
|
Stephen F. Betz Chief Scientific Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
1,410
-1.6%
|
$23,970
$17.12 P/Share
|
|
Mar 16
2023
|
Jeff E. Knight Chief Operating Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
587
-1.68%
|
$9,979
$17.12 P/Share
|
|
Mar 16
2023
|
Alan Seth Krasner Chief Medical Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
1,687
-3.84%
|
$28,679
$17.12 P/Share
|
|
Mar 01
2023
|
James Hassard Chief Commercial Officer |
BUY
Grant, award, or other acquisition
|
Direct |
14,000
+50.0%
|
-
|
|
Mar 01
2023
|
Stephen F. Betz Chief Scientific Officer |
BUY
Grant, award, or other acquisition
|
Direct |
23,600
+21.09%
|
-
|
|
Mar 01
2023
|
Alan Seth Krasner Chief Medical Officer |
BUY
Grant, award, or other acquisition
|
Direct |
19,500
+30.71%
|
-
|
|
Mar 01
2023
|
Dana Pizzuti Chief Med and Dev Officer |
BUY
Grant, award, or other acquisition
|
Direct |
4,500
+20.93%
|
-
|
|
Mar 01
2023
|
Marc Wilson CFO |
BUY
Grant, award, or other acquisition
|
Direct |
24,200
+18.34%
|
-
|
|
Mar 01
2023
|
Jeff E. Knight Chief Operating Officer |
BUY
Grant, award, or other acquisition
|
Direct |
29,500
+45.75%
|
-
|
|
Mar 01
2023
|
Richard Scott Struthers President & CEO |
BUY
Grant, award, or other acquisition
|
Direct |
61,650
+32.14%
|
-
|
|
Feb 01
2023
|
Stephen F. Betz Chief Scientific Officer |
SELL
Open market or private sale
|
Direct |
3,126
-4.61%
|
$59,394
$19.59 P/Share
|
|
Jan 25
2023
|
Stephen F. Betz Chief Scientific Officer |
SELL
Open market or private sale
|
Direct |
8,336
-10.95%
|
$175,056
$21.07 P/Share
|
|
Jan 17
2023
|
Stephen F. Betz Chief Scientific Officer |
SELL
Open market or private sale
|
Direct |
3,126
-3.94%
|
$56,268
$18.0 P/Share
|
|
Jan 03
2023
|
Stephen F. Betz Chief Scientific Officer |
SELL
Open market or private sale
|
Direct |
3,126
-3.79%
|
$56,268
$18.35 P/Share
|